These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Therapeutic effects of risedronate on Paget's disease of bone].
    Author: Takata S.
    Journal: Clin Calcium; 2006 Sep; 16(9):1508-12. PubMed ID: 16951476.
    Abstract:
    Paget's disease of bone (PDB) is a chronic disorder characterized by focal abnormalities of bone turnover. The characteristic feature of PDB is excessive osteoclastic bone resorption coupled to increased and disorganized bone formation. Although PDB is rare in Japan, it is quite common in most European countries, except for Scandinavia. The recommended regimens for bisphosphonates use in various parts of the world. Calcitonin and etidronate are approved by the Ministry of Health, Labour and Welfare in Japan to treat PDB. Risedronate is currently under development for use in the treatment of PDB in Japan.
    [Abstract] [Full Text] [Related] [New Search]